W celu świadczenia usług na najwyższym poziomie stosujemy pliki cookies. Korzystanie z naszej witryny oznacza, że będą one zamieszczane w Państwa urządzeniu. W każdym momencie można dokonać zmiany ustawień Państwa przeglądarki. Zobacz politykę Cookies

X

News

06 March, 2025

Position of the Transparency Council – Fasenra (benralizumab)

13 January, 2025

Communication from AOTMIT on submission of PICO information for joint clinical assessment

18 April, 2025

Publication AWA

18 April, 2025

Status of work in April

17 April, 2025

Recommendation of the President – Lamprene (clofazimine)

16 April, 2025

Opinion of the Transparency Council – posaconazole

16 April, 2025

Opinion of the Transparency Council – posaconazole

16 April, 2025

Opinion of the Transparency Council – lacosamide

16 April, 2025

Opinion of the Transparency Council – peginterferon alfa-2a

16 April, 2025

Opinion of the Transparency Council – carbamazepine

16 April, 2025

Position of the Transparency Council – Albendazol Micro Labs

16 April, 2025

Position of the Transparency Council – Xyrem (sodium oxybate)

16 April, 2025

Position of the Transparency Council – Tagrisso (osimertinib)

16 April, 2025

Opinion of the Transparency Council – Treatment of Gaucher disease type I and type III (ICD-10 E 75.2)

16 April, 2025

Position of the Transparency Council – Fabhalta (iptacopan)

16 April, 2025

Tariff Council meeting 4/2025 on 17 April 2025

14 April, 2025

The Transparency Council meeting 16/2025 on 22 April 2025

11 April, 2025

Status of work in April

11 April, 2025

Publication AWA

11 April, 2025

Recommendation of the President – Voydeya (danicopan)

09 April, 2025

Opinion of the Transparency Council – olanzapine

09 April, 2025

Opinion of the Transparency Council – haloperidolum

09 April, 2025

Opinion of the Transparency Council – prednisonum

09 April, 2025

Position of the Transparency Council – Mestinon Retard (pyridostigmini bromidum) and Mestinon (pyridostigmini)

Home page

News Publications Publikacje BIP

#webinar agenda Aktualności announcement of the President azathioprinum Bimzelx Collegium AOTMiT colorectal cancer communication Communication from the Transparency Council Communication on the Tariff Council Cost Accounting Standard Council for Tariffs Affairs covering neonatal care cyclophosphamidum Data acquisition dental treatment services diseases of the organ of vision drug programme Empliciti entecavirum etanercept Fycompa gastroscopy glaucoma health policy program health policy programme health policy programme on breast cancer health policy programme on infertility treatment Health Policy Programmes Impavido in vitro Inovelon Jardiance Meeting of the Transparency Council methotrexatum Milupa Basic-P minimum wage increases mycophenolate mofetil new new tariffs news Notice Notice of the President Ontozry Onureg Opdivo Opdivo (nivolumab)opinion Opinion of the President Opinion of the Transparency Council Ospolot Ozurdex perinatal care Ponvory Position of the Transparency Council Press conference Recommendation Recommendation of the President Renastep report Rezurock sirolimus Suliqua Tariff Council Tariffs Council Tarification Plan 2025 tenofovirum disoproxilum the drug programme B.44 the drug programme B.82 The Meeting of the Tariffs Council trainings Transparency Council Tremfya update Vivitrol Yervoy

Pokaż więcej ↓

Pokaż mniej ↑